All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Theramex’s menopause-induced osteoporosis peptide lands UK’s NICE recommendation (Eladynos)
Synthetic peptide, osteoporosis, menopause - Read more

THE GOOD
Business Development

Pathos AI buys worldwide license to Prelude Therapeutics PRMT5 inhibitor (PRT811)
Small molecule, solid tumor, glioma, melanoma, cancer - Read more

ArriVent BioPharma opts to license cancer asset as part of 2.5 years old $100M partnership with Aarvik Therapeutics
Antibody-drug conjugate, oncology, cancer - Read more

THE GOOD
Clinical Trials

DermBiont showcases initial positive Ph2a carcinoma trial data (SM-020)
Small molecule, topical, gorlin syndrome, carcinoma, cancer - Read more

Turnstone Biologics posts promising Ph1 TIL data, though financial concern sink stock
Tumor-infiltrating lymphocyte (TIL), cell therapy, colorectal cancer, head and neck cancer, uveal melanoma - Read more

THE GOOD
Earnings & Finances

A public health emergency is great news for Bavarian Nordic shareholders as stock jumps nearly 50% over the last week
Vaccine, infectious disease outbreak, monkeypox (mpox) - Read more

THE GOOD
Fundraises

Kalm Therapeutics $700k seed raise
Non-steroidal topical, medical device, atopic dermatitis, psoriasis - Read more

HistoSonics turns it up louder with $102M Series D for ultrasound-powered liver cancer treatment
Medical device, ultrasound, liver cancer - Read more

ViroCell Biologics complete oversubscribed financing round, terms undisclosed
CDMO, cell and gene therapy - Read more

THE GOOD
Investments

Abata Therapeutics nabs strategic investment from Bristol Myers Squibb
Regulatory T cells (Treg), autoimmune, type 1 diabetes, primary progressive multiple sclerosis (PPMS) - Read more

Insulet debuts 400k sqft insulin delivery device manufacturing site in Malaysia
Medical device, insulin delivery, diabetes, manufacturing - Read more

PRESENTED BY THE UBC SCHOOL OF BIOMEDICAL ENGINEERING
Unlock the Future of Healthcare Innovation

Join us online on Wednesday, September 25th, at 5:30 PM Pacific for an information session about UBC's new Micro-certificate in Innovation Leadership: Medical & Bio-Innovations.

Discover how this transformative program equips you with essential legal, strategic, and practical skills to bridge the gap between scientific breakthroughs and market success.

What to Expect:

• Learn about the unique opportunities this program offers to advance your career.

• Understand how to make a meaningful impact on healthcare.

• Participate in a live Q&A session.

Don’t miss this opportunity—register now to secure your spot!🔗 

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Partnerships

Zealand Pharma’s looking for a commercial partner for their obesity asset (petrelintide)
GLP-1/GLP-2, obesity - Read more

Nanoform collabs with Takeda on plasma-derived therapy development
Plasma-derived therapy, drug delivery, rare disease - Read more

NorthStar Medical Radioisotopes, Convergent Therapeutics strategic collab (CONV01-α)
Monoclonal antibody-radioisotope conjugate, radiopharma, prostate cancer - Read more

Nuntius Therapeutics, Taiho Pharmaceutical mRNA-based therapy cell-specific delivery collab
mRNA, cells-specific drug delivery, cancer, neurodegenerative diseases - Read more

THE GOOD
Politics & Policy

Medicare unveils first round of drug price negotiations enabled by the IRA
Inflation reduction act, drug pricing - Read more

THE GOOD
Research

Scale Biosciences launches “100 Million Cell Challenge”
Single cell projects, RNA sequencing, high-throughput sequencing - Read more

Denali Therapeutics showcases new brain drug delivery tech; animal studies
Engineered antibody, drug delivery, blood-brain barrier - Read more

Blackrock Neurotech’s brain implant (+ AI) returns voice to ALS patient
Medical device, brain implant, brain-computer interface, amyotrophic lateral sclerosis (ALS) - Read more

THE GOOD
Strategic Plans

Bayer’s massive restructuring not slowing down dealmaking according to BD head - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trals

SIGA Technologies Tpoxx antiviral misses primary endpoint, though CEO mentions this was “not entirely unexpected“
Small molecule, smallpox, monkeypox (mpox) - Read more

THE BAD
Lawsuits

Pfizer’s $107.5M Tagrisso patent win against AstraZeneca thrown out by Delaware judge
Small molecule, lung cancer, drug patent - Read more

THE BAD
Layoffs

Lykos Therapeutics can’t catch a break, as they cut 75% of their staff (including it’s Founder)
Small molecule, psychedelic, MDMA, depression - Read more 

THE BAD
Research

How good is AI in drug discovery? Not great, according to recent Leash Bio contest
AI, drug discovery - Read more [Read more]

THE BAD
Strategic Plans

Lyra Therapeutics pauses LYR-220 development in an effort to refocus
Small molecule, chronic rhinosinusitis, nasal mesh, drug delivery - Read more

THE UGLY
Withdrawals & Recalls

Two separate injectable sodium chloride solution recalls from B. Braun (particulate concerns) and Baxter (endotoxin concerns)
Sodium chloride solution injectable, metabolic alkalosis, anticoagulant - Read more 

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.